Back to Top Skip to main content

Health.mil: the official website of the Military Health System (MHS) and the Defense Health Agency (DHA)

Utility Navigation Links

Need larger text?
TRICARE Policy Manual 6010.60-M, April 1, 2015
Other Services
Chapter 8
Section 2.5
Home Prothrombin Time (PT) International Normalized Ratio (INR) Monitor
Issue Date:  March 3, 2005
Authority:  32 CFR 199.2 and 32 CFR 199.4(d)(3)(ii)
Revision:  
1.0  HCPCS PROCEDURE CODES
G0248, G0249, G0250
2.0  DESCRIPTION
Home PT INR monitoring devices are portable, battery-operated, hand-held analyzing systems designed for testing a small sample of fresh, capillary whole blood obtained by a finger-stick using a lancet device. Depending on the system, the drop of blood is placed on a test strip or disposable reagent cuvette. A new test strip or reagent cartridge must be used with each test performed. Once clotting is initiated, PT is determined by different ways depending on the device:
•  By cessation of blood flow;
•  By changes in light transmission;
•  Through use of fluorescent thrombin substrate.
3.0  POLICY
3.1  Home PT INR monitors may be covered for patients meeting the following criteria:
3.1.1  The patient must have a medical condition requiring lifetime warfarin therapy and monitoring of prothrombin time activity.
3.1.2  The patient must need to have frequent prothrombin time testing once a week or multiple times per month.
3.1.3  The patient (or patient’s caregiver) must have the ability to use the prothrombin time monitoring device after obtaining education on its proper use from an appropriate health care professional.
3.2  The monitor must be prescribed by a physician.
3.3  The device must have U.S. Food and Drug Administration (FDA) approval.
3.4  Related services and supplies, such as PT test strips and office visits, are covered.
3.5  Education or demonstration related to the use of the device is considered incidental to the office visit or the provision of the materials and equipment. Additional reimbursement is not warranted.
4.0  EFFECTIVE DATE
Date of FDA approval of the device.
- END -

Utility Navigation Links

DoD Seal

tricare.mil is the official website of the Defense Health Agency (DHA) a component of the Military Health System

TRICARE is a registered trademark of the Department of Defense (DoD), DHA. All rights reserved.

CPT only © 2006 American Medical Association (or such other date of publication of CPT). All Rights Reserved.

If you have a question regarding TRICARE benefits, please go to the TRICARE Contact Us page page.
If you need help with technical/operational issues, please go to the TRICARE Manuals Online Help page.

The appearance of hyperlinks to external websites does not constitute endorsement by the DHA of these websites or the information, products or services contained therein. For other than authorized government activities, the DHA does not exercise any editorial control over the information you may find at other locations. Such links are provided consistent with the stated purpose of this DoD website.

v4.11.8372.15705

DHA Address: 7700 Arlington Boulevard | Suite 5101 | Falls Church, VA | 22042-5101

Some documents are presented in Portable Document Format (PDF). A PDF reader is required for viewing. Download a PDF Reader or learn more about PDFs.
You are leaving Health.mil The appearance of hyperlinks does not constitute endorsement by the Defense Health Agency of non-U.S. Government sites or the information, products, or services contained therein. Although the Defense Health Agency may or may not use these sites as additional distribution channels for Department of Defense information, it does not exercise editorial control over all of the information that you may find at these locations. Such links are provided consistent with the stated purpose of this website. You are leaving Health.mil View the external links disclaimer. OK Cancel